Celldex Therapeutics (CLDX) stock snapshot

Celldex Therapeutics (CLDX) has drawn fresh attention after recent trading moves, with the stock showing a 6.3% gain over the past month and a 40.2% return in the past 3 months.

Despite a 3.1% one day share price pullback to US$33.32, Celldex’s recent 30 day share price return of 6.3% and 90 day share price return of 40.2% point to building momentum. The 1 year total shareholder return of 70.7% shows how strongly the stock has rewarded holders over a longer stretch.

If you are weighing Celldex’s move against other healthcare opportunities, this is a good moment to see what else is gaining traction through 35 healthcare AI stocks

With Celldex trading at US$33.32 against a US$57.00 analyst target and an indicated intrinsic discount of roughly 60%, you have to ask: is this a genuine mispricing, or is the market already baking in future growth?

Preferred Price-to-Book of 5x: Is it justified?

On our data, Celldex is trading on a P/B of 5x, which sits above both the US biotech industry and its closest peers despite the recent share price pullback.

P/B compares the market value of a company to the accounting value of its net assets. It is often used for early stage or unprofitable businesses where earnings are not yet a reliable guide.

For Celldex, a 5x P/B suggests investors are placing a high value on the company’s pipeline and future potential despite current losses and limited reported revenue. The market is paying a premium to the industry average of 2.5x and the peer average of 3.9x.

That premium is clear, with Celldex’s P/B multiple essentially double the broader biotech industry and meaningfully above closer peers. This indicates the market is currently pricing the stock at a higher level than more typical balance sheet based valuations in the sector.

Result: Price-to-book of 5x (OVERVALUED)

However, there are clear risks, including Celldex’s US$258.757 million net loss and reliance on a small pipeline that could face clinical or regulatory setbacks.

Another view on valuation

The 5x P/B suggests Celldex screens as expensive on assets, but our DCF model points the other way. On this approach, the stock trades at $33.32 versus an estimated future cash flow value of $83.91, which implies it is undervalued. Which signal do you rely on when they pull in opposite directions?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Celldex Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals can make Celldex hard to read, so if this story interests you, it is worth checking both the risks and the upside. To see the full balance, review the 2 key rewards and 3 important warning signs

Ready to uncover more investment ideas?

If Celldex has caught your eye, do not stop there. Broaden your watchlist with other stocks that match clear, disciplined criteria using these focused screens.

• Target resilience first by checking companies that appear in the 72 resilient stocks with low risk scores to see which stocks currently carry lower overall risk scores.
• Spot potential value by scanning the screener containing 23 high quality undiscovered gems and see which under-the-radar stocks currently pair stronger fundamentals with less attention.
• Prioritise financial strength by using the solid balance sheet and fundamentals stocks screener (44 results) and focus on companies showing healthier balance sheets and steadier fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.